Diaminoalkane aspartic protease inhibitors

US8455521B2 · kind B2 · utility

Assignee

• Vitae Pharmaceuticals, LLC · US

Inventors

• John J. Baldwin · Gwynedd Valley, US
• David A. Claremon · Audubon, US
• Colin M. Tice · Ambler, US
• Salvacion Cacatian · Conshohocken, US
• Lawrence Wayne Dillard · Yardley, US
• Alexey V. Ishchenko · Somerville, US
• Jing Yuan · Lansdale, US
• Zhenrong Xu · Forest Park, US
• Gerard McGeehan · Chester Springs, US
• Wei Zhao · North Potomac, US
• Robert D. Simpson · Wilmington, US
• Suresh B. Singh · Kendall Park, US
• Patrick T. Flaherty · Pittsburgh, US
• Jean-Pierre Wery · San Diego, US

Key dates

• Filing date: May 28, 2010
• Grant date: Jun 4, 2013
• Expiry date: Jul 27, 2030

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Diaminoalkanes of below Formula I have now been found which are orally active and bind to aspartic proteases to inhibit their activity:They are useful in the treatment or amelioration of diseases associated with elevated levels of aspartic protease activity. The invention also relates to a method for the use of the compounds of Formula I in ameliorating or treating aspartic protease related disorders in a subject in need thereof comprising administering to said subject an effective amount of a compound of Formula I.